Tetrameric Cytokine-Antibody Complexes via Dock-and-Lock Technology
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cytokines such as IFNα2b, G-CSF, and erythropoietin face challenges due to their short circulating half-life and systemic toxicity, limiting their therapeutic efficacy and requiring frequent dosing, while existing fusion with monoclonal antibodies does not fully address targeting and retention issues for cancer therapy.
Innovation Solution
The Dock-and-Lock (DNL) method is used to create stable, tetrameric cytokine-IgG complexes by site-specific conjugation of cytokines with a dimerization and docking domain (DDD) moiety to an anchor domain (AD) moiety, anchored on a humanized monoclonal antibody, enhancing in vivo efficacy and targeting specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytokines are administered systemically, then therapeutic efficacy is achieved, but circulating half-life is short and systemic toxicity occurs
Solution Approach 1:
The patent combines cytokines with antibody Fc regions to create fusion proteins that leverage the long circulating half-life of antibodies while delivering cytokine therapeutic activity. This merging of two different biomolecules resolves the contradiction by providing both efficacy and prolonged duration of action.
Solution Approach 2:
The invention creates composite biomolecular structures where cytokine domains are fused with antibody Fc domains. This composite structure combines the therapeutic properties of cytokines with the pharmacokinetic advantages of antibodies, achieving both efficacy and extended half-life.
2Reliability
If cytokines are administered systemically, then therapeutic efficacy is achieved, but systemic toxicity increases
Solution Approach 1:
The patent engineering cytokine-Fc fusion proteins that can be targeted to specific tissues or cells through antibody binding, concentrating therapeutic activity at the disease site while reducing systemic exposure. This localizes the therapeutic effect and minimizes systemic toxicity.
Solution Approach 2:
The antibody Fc portion acts as an intermediary that directs the cytokine to specific targets through antigen binding, mediating between systemic administration and localized therapeutic action. This reduces off-target effects and systemic toxicity.
3Reliability
If cytokines are administered frequently, then therapeutic efficacy is maintained, but treatment complexity increases
Solution Approach 1:
By merging cytokine activity with the long half-life of antibody-Fc structures, the invention enables less frequent dosing while maintaining therapeutic efficacy. The extended circulation time of the Fc fusion protein reduces dosing frequency and treatment complexity.
4Measurement precision
If monoclonal antibodies are used for targeted delivery, then specificity is improved, but bioavailability and prolonged action are not fully achieved
Solution Approach 1:
The invention merges the targeting capability of monoclonal antibodies with the cytokine therapeutic function in a single fusion protein. The antibody portion provides specificity while the cytokine provides therapeutic activity, and the Fc region contributes to prolonged bioavailability.
Solution Approach 2:
The cytokine-Fc fusion protein performs multiple functions simultaneously: targeting via antibody binding, therapeutic action via cytokine activity, and prolonged circulation via Fc half-life extension. This multi-functionality resolves the contradiction between specificity and duration.
Data Source
AI summary
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.